Qureator
San Diego, US · Delaware corporation
Find your way into Qureator
Sign up to see every warm intro you have to Qureator
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Qureator team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Qureator develops non-animal testing methods for drug development, notably achieving an FDA IND approval without animal proof-of-concept data in collaboration with SillaJen. The company works in preclinical biotech, providing alternatives to animal testing for pharmaceutical partners.
Founders & leadership
KB

Kyusuk BaekFounder
PP

Paul ParkConsulting Chief Business Officer
NL
Noo Li JeonNamed on SEC filing
Reported raises · per SEC filings
Form D private placements$6.7M disclosed across 1 round · 2025
▶$6.7MraisedMar 2026 · 1 investors · BiotechnologyRule 506(b)
▶$6.7MraisedMar 2026 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Kyusuk BaekExecutive Officer, Director
- Noo Li JeonDirector
- Offering amount
- $6.9M
- Amount sold
- $6.7M
- First sale
- Dec 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 3
Cour PharmaCOUR develops antigen-specific immunotherapies that reprogram the immune system to treat the underlying causes of autoimmune and immune-mediated diseases while preserving normal immune function. The company is advancing a pipeline of disease-modifying therapies aimed at patients with a range of autoimmune conditions.
Applied TherapeuticsApplied Therapeutics is a biopharmaceutical company developing novel drugs for rare diseases with high unmet medical need. Its Aldose Reductase Inhibitor franchise is in development across disease areas including Galactosemia and SORD Deficiency.
QuralisQurAlis develops precision therapies for amyotrophic lateral sclerosis (ALS) and related neurodegenerative diseases by targeting specific disease-causing genetic drivers and molecular mechanisms. The company was founded by neuroscientists from Harvard to translate emerging discoveries about disease pathways into treatment breakthroughs for ALS patients.
Companies working in the same space as Qureator.
Frequently asked questions
- What does Qureator do?
- Qureator develops non-animal testing methods for drug development, notably achieving an FDA IND approval without animal proof-of-concept data in collaboration with SillaJen. The company works in preclinical biotech, providing alternatives to animal testing for pharmaceutical partners.
- Who founded Qureator?
- Qureator was founded by Kyusuk Baek.
- How much funding has Qureator raised?
- Qureator has disclosed $6.7M raised across 1 round.
- Where is Qureator headquartered?
- Qureator is headquartered in San Diego, US.

